SGK
CHRS icon

Steigerwald Gordon & Koch’s Coherus Oncology CHRS Stock Holding History

Steigerwald Gordon & Koch’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4K Hold
1,000
– – ﹤0.01% 707
2026
Q1 		$1.69K Hold
1,000
– – ﹤0.01% 699
2025
Q4 		$1.42K Hold
1,000
– – ﹤0.01% 836
2025
Q3 		$1.64K Buy
+1,000
New +$1.11K ﹤0.01% 732

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Steigerwald Gordon & Koch's CHRS Position: Q2 2026 in Review

Steigerwald Gordon & Koch held its Coherus Oncology (CHRS) position steady in Q2 2026 at 1,000 shares worth $1.4K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

Steigerwald Gordon & Koch first reported a position in CHRS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.69K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Steigerwald Gordon & Koch held 1,000 shares of Coherus Oncology worth $1.4K as of Q2 2026.
  • Steigerwald Gordon & Koch left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #707 holding.
  • Steigerwald Gordon & Koch first reported a position in Coherus Oncology in Q3 2025 and has held it in 4 quarters since.
  • Steigerwald Gordon & Koch's Coherus Oncology position peaked at $1.69K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.